Davis C Teichgraeber, Roland L Bassett, Gary J Whitman
{"title":"二诊 US 对评估异常分子乳腺成像结果的实用性:回顾性研究。","authors":"Davis C Teichgraeber, Roland L Bassett, Gary J Whitman","doi":"10.1093/jbi/wbae059","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to evaluate the utility of US for identifying and characterizing lesions detected on molecular breast imaging (MBI).</p><p><strong>Methods: </strong>A retrospective single-institution review was performed of patients with MBI studies with subsequent US for abnormal MBI findings between January 1, 2015, and September 30, 2021. Medical records, imaging, and histopathology were reviewed. The reference standard was histopathology and/or imaging follow-up. Associations among MBI findings, the presence of an US correlate, and histopathology were evaluated by Fisher exact tests.</p><p><strong>Results: </strong>The 32 lesions detected on MBI in 25 patients were evaluated by US, and 19 lesions had an US correlate (19/32, 59%). Mass uptake was more likely to have an US correlate (11/13, 85%; P = .02) than nonmass uptake (7/19, 37%), and mass uptake was more likely to be malignant (5/13, 38%; P = .01). Of the 13 lesions without an US correlate, 5 were evaluated and subsequently biopsied by MRI (2 high-risk lesions and 3 benign lesions). Follow-up MBIs demonstrated stability/resolution for 5 lesions in 4 patients at 6 months or longer. Three patients had no further imaging.</p><p><strong>Conclusion: </strong>Mass lesions identified on MBI were more likely to have an US correlate and were more likely to be malignant than nonmass lesions.</p>","PeriodicalId":43134,"journal":{"name":"Journal of Breast Imaging","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Utility of Second-Look US to Evaluate Abnormal Molecular Breast Imaging Findings: A Retrospective Study.\",\"authors\":\"Davis C Teichgraeber, Roland L Bassett, Gary J Whitman\",\"doi\":\"10.1093/jbi/wbae059\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>The purpose of this study was to evaluate the utility of US for identifying and characterizing lesions detected on molecular breast imaging (MBI).</p><p><strong>Methods: </strong>A retrospective single-institution review was performed of patients with MBI studies with subsequent US for abnormal MBI findings between January 1, 2015, and September 30, 2021. Medical records, imaging, and histopathology were reviewed. The reference standard was histopathology and/or imaging follow-up. Associations among MBI findings, the presence of an US correlate, and histopathology were evaluated by Fisher exact tests.</p><p><strong>Results: </strong>The 32 lesions detected on MBI in 25 patients were evaluated by US, and 19 lesions had an US correlate (19/32, 59%). Mass uptake was more likely to have an US correlate (11/13, 85%; P = .02) than nonmass uptake (7/19, 37%), and mass uptake was more likely to be malignant (5/13, 38%; P = .01). Of the 13 lesions without an US correlate, 5 were evaluated and subsequently biopsied by MRI (2 high-risk lesions and 3 benign lesions). Follow-up MBIs demonstrated stability/resolution for 5 lesions in 4 patients at 6 months or longer. Three patients had no further imaging.</p><p><strong>Conclusion: </strong>Mass lesions identified on MBI were more likely to have an US correlate and were more likely to be malignant than nonmass lesions.</p>\",\"PeriodicalId\":43134,\"journal\":{\"name\":\"Journal of Breast Imaging\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-10-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Breast Imaging\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/jbi/wbae059\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Breast Imaging","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jbi/wbae059","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的本研究旨在评估 US 在识别和描述分子乳腺成像(MBI)检测到的病变方面的实用性:方法:对2015年1月1日至2021年9月30日期间接受分子乳腺成像检查的患者进行了单机构回顾性研究,随后对异常的分子乳腺成像结果进行了US检查。对病历、影像学和组织病理学进行了审查。参考标准为组织病理学和/或成像随访。通过费舍尔精确检验评估了MBI结果、US相关性和组织病理学之间的关联:结果:25 名患者在 MBI 上发现的 32 个病灶均接受了 US 评估,其中 19 个病灶与 US 相关(19/32,59%)。与非肿块摄取(7/19,37%)相比,肿块摄取更有可能与 US 相关(11/13,85%;P = .02),肿块摄取更有可能是恶性的(5/13,38%;P = .01)。在 13 个没有 US 相关性的病灶中,有 5 个进行了评估,随后通过 MRI 进行了活检(2 个高风险病灶和 3 个良性病灶)。随访 MBI 显示,4 名患者的 5 个病灶在 6 个月或更长时间内稳定/消退。结论:结论:与非肿块病变相比,MBI 发现的肿块病变更有可能与 US 相关,也更有可能是恶性的。
The Utility of Second-Look US to Evaluate Abnormal Molecular Breast Imaging Findings: A Retrospective Study.
Objective: The purpose of this study was to evaluate the utility of US for identifying and characterizing lesions detected on molecular breast imaging (MBI).
Methods: A retrospective single-institution review was performed of patients with MBI studies with subsequent US for abnormal MBI findings between January 1, 2015, and September 30, 2021. Medical records, imaging, and histopathology were reviewed. The reference standard was histopathology and/or imaging follow-up. Associations among MBI findings, the presence of an US correlate, and histopathology were evaluated by Fisher exact tests.
Results: The 32 lesions detected on MBI in 25 patients were evaluated by US, and 19 lesions had an US correlate (19/32, 59%). Mass uptake was more likely to have an US correlate (11/13, 85%; P = .02) than nonmass uptake (7/19, 37%), and mass uptake was more likely to be malignant (5/13, 38%; P = .01). Of the 13 lesions without an US correlate, 5 were evaluated and subsequently biopsied by MRI (2 high-risk lesions and 3 benign lesions). Follow-up MBIs demonstrated stability/resolution for 5 lesions in 4 patients at 6 months or longer. Three patients had no further imaging.
Conclusion: Mass lesions identified on MBI were more likely to have an US correlate and were more likely to be malignant than nonmass lesions.